Literature DB >> 29032029

CXCR5+CD8+ T cells could induce the death of tumor cells in HBV-related hepatocellular carcinoma.

Yun Jin1, Cuicui Lang2, Jianzhong Tang1, Jiawei Geng3, Haihan K Song4, Zhiwei Sun5, Jinfeng Wang6.   

Abstract

The follicular CXCR5+CD8+ T cells have recently emerged as a critical cell type in mediating peripheral tolerance as well as antiviral immune responses during chronic infections. In this study, we investigated the function of CXCR5+CD8+ T cells in HBV-related hepatocellular carcinoma patients. Compared to CXCR5-CD8+ T cells, CXCR5+CD8+ T cells presented elevated PD-1 expression but reduced Tim-3 and CTLA-4 expression. Upon anti-CD3/CD28 stimulation, CXCR5+CD8+ T cells demonstrated higher proliferation potency than CXCR5-CD8+ T cells, especially after PD-1 blockade. CXCR5+CD8+ T cells also demonstrated significantly higher granzyme B synthesis and release, as well as higher level of degranulation. Tumor cells were more readily eliminated by CXCR5+CD8+ T cells than by CXCR5-CD8+ T cells. Interestingly, we found that B cells were more resistant to CXCR5+CD8+ T cell-mediated killing than tumor cells, possibly through IL-10-mediated protection. In addition, the CXCR5+CD8+ T cell-mediated cytotoxic effects on tumor cells could be significantly enhanced by PD-L1 blockade. Together, we presented that in patients with in HBV-related hepatocellular carcinoma, CXCR5+CD8+ T cells could mediate tumor cell death more potently than the CXCR5-CD8+ T cells in vitro while the autologous B cells were protected.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  B cells; CXCR5(+)CD8(+) T cells; HBV; Hepatocellular carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29032029     DOI: 10.1016/j.intimp.2017.10.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  13 in total

1.  Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer.

Authors:  Qin-Yun Ma; Jun Chen; Jun Zhao
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 2.  Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.

Authors:  Katarzyna Szklener; Adam Michalski; Klaudia Żak; Michał Piwoński; Sławomir Mańdziuk
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

3.  Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer.

Authors:  Jieti Wang; Ruochen Li; Yifan Cao; Yun Gu; Hanji Fang; Yuchao Fei; Kunpeng Lv; Xudong He; Chao Lin; Hao Liu; Heng Zhang; He Li; Hongyong He; Jiejie Xu; Hua Huang
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

Review 4.  CXCR5+CD8+ T cells: A Review of their Antibody Regulatory Functions and Clinical Correlations.

Authors:  Steven M Elzein; Jason M Zimmerer; Jing L Han; Bryce A Ringwald; Ginny L Bumgardner
Journal:  J Immunol       Date:  2021-06-15       Impact factor: 5.426

Review 5.  Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.

Authors:  Selena Vigano; Sara Bobisse; George Coukos; Matthieu Perreau; Alexandre Harari
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 6.  Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology.

Authors:  Lei Qin; Tayab C Waseem; Anupama Sahoo; Shayahati Bieerkehazhi; Hong Zhou; Elena V Galkina; Roza Nurieva
Journal:  Front Immunol       Date:  2018-08-15       Impact factor: 7.561

Review 7.  CXCR5+ CD8 T Cells: Protective or Pathogenic?

Authors:  Kristen M Valentine; Katrina K Hoyer
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

8.  CD8 follicular T cells localize throughout the follicle during germinal center reactions and maintain cytolytic and helper properties.

Authors:  Kristen M Valentine; Genevieve N Mullins; Oscar A Davalos; Lek Wei Seow; Katrina K Hoyer
Journal:  J Autoimmun       Date:  2021-07-16       Impact factor: 14.511

9.  Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5+ CD8+ T cell abundance.

Authors:  Qiuren Huang; Quan Zhou; Hongyu Zhang; Zhaopei Liu; Han Zeng; Yifan Chen; Yang Qu; Ying Xiong; Jiajun Wang; Yuan Chang; Yu Xia; Yiwei Wang; Li Liu; Yu Zhu; Le Xu; Bo Dai; Jianming Guo; Zewei Wang; Qi Bai; Weijuan Zhang
Journal:  Oncoimmunology       Date:  2020-08-28       Impact factor: 8.110

10.  Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection.

Authors:  Wei-Ren Liu; Meng-Xin Tian; Zheng Tang; Yuan Fang; Yu-Fu Zhou; Shu-Shu Song; Xi-Fei Jiang; Han Wang; Chen-Yang Tao; Pei-Yun Zhou; Wei-Feng Qu; Zhen-Bin Ding; Yuan-Fei Peng; Jian Zhou; Jia Fan; Ying-Hong Shi
Journal:  Br J Cancer       Date:  2020-05-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.